AuguryMenarini’s Elacestrant Combo Data at SABCS Hints at a Role in ER+, HER2- Metastatic Breast Cancer — But Big Questions Remain
This article was written by the Augury Times
At the San Antonio Breast Cancer Symposium (SABCS) 2025, Menarini Group presented Phase 2 results testing elacestrant (ORSERDU) in combination with other agents for ER+, HER2- metastatic breast cancer. The company framed the data as supportive of further development: combination cohorts showed signs of tumor shrinkage in an endocrine-resistant population and a safety profile Menarini described as manageable. The talk was clearly aimed at positioning ORSERDU as a backbone for combinations rather than a stand‑alone blockbuster.
What Menarini told the conference and why it matters
Menarini used SABCS to show how elacestrant performs when paired with other drugs in patients who have already progressed on standard endocrine therapies. That matters because the field is crowded with endocrine resistance — tumors that stop responding to aromatase inhibitors or selective estrogen receptor degraders (SERDs). If ORSERDU can restore control of disease in meaningful numbers of patients, it can become a go‑to option for combinations and extend the life of endocrine‑based approaches. The company emphasized tolerability and potential signals of benefit, but the materials I have do not include the exact numeric readouts published at the meeting. I can update the piece with precise figures if you want me to pull the full presentation text or press release.
What the Phase 2 numbers actually show: response, duration and tolerability
Menarini reported efficacy and safety across several Phase 2 combination cohorts, focusing on patients with ER+, HER2- disease who had prior endocrine therapy. The key endpoints for these cohorts were objective response rate (ORR), clinical benefit rate (CBR), and measures of how long responses lasted (duration of response, DOR) or how long patients lived without progression (progression‑free survival, PFS). According to the company’s presentation summary, combination arms produced measurable tumor shrinkage in a meaningful subset of patients, with benefit concentrated in biomarker‑defined groups such as those with ESR1 mutations.
On safety, Menarini described a tolerability profile consistent with oral SERD class effects and with the partner drugs used in each cohort. Most adverse events were reported as low‑to‑moderate grade and manageable with dose adjustments. The company flagged predictable toxicities tied to the partner agents rather than new, unexpected signals from elacestrant itself. Because the full numeric tables and confidence intervals were not included in the brief I received, I can’t report exact percentages or medians here — and follow‑up is still relatively short, so time‑to‑event measures are immature and should be read cautiously.
Where ORSERDU could slot into the ER+, HER2- treatment landscape
Endocrine therapy remains the backbone for ER+ disease, often combined with CDK4/6 inhibitors, PI3K inhibitors for PIK3CA‑mutant tumors, or mTOR inhibitors. Elacestrant arrived as an oral SERD intended to overcome resistance driven by ESR1 mutations or other mechanisms. If the Phase 2 combos show consistent benefit, ORSERDU’s clearest role is as the endocrine backbone in later‑line combinations — for example, replacing fulvestrant or earlier SERDs in regimens that pair endocrine therapy with targeted agents.
Competitors and comparators include oral and injectable SERDs in development, CDK4/6 inhibitor combinations, and antibody‑drug conjugates that are reshaping late‑line care. Menarini will need to demonstrate either a clear efficacy edge, better tolerability, or simpler dosing to carve out durable market share. Based on the tone of the SABCS presentation, Menarini’s strategy is incremental: position ORSERDU as a tolerant, orally dosed partner that can be combined widely rather than a single agent that displaces established standards overnight.
Development program and key regulatory milestones to track
Menarini is running multiple trials with elacestrant beyond these Phase 2 combos. The agendas discussed at SABCS included ongoing metastatic trials and exploratory work in earlier disease settings. The most important upcoming milestones for investors will be mature pivotal data readouts from randomized studies and any regulatory filings or breakthrough designations tied to positive Phase 3 results. Expect company updates on enrollment timetables, interim analyses, and plans to move promising combinations into registrational testing. Menarini’s next step logically is to take the most convincing combo into a larger randomized trial against the current standard.
Investor implications: market opportunity, competitors and commercial scenarios
From a market perspective, the ER+, HER2- metastatic breast cancer space still represents a sizable opportunity because endocrine‑based care is used widely and resistance creates repeated demand for new options. If elacestrant proves to be a reliable oral SERD in combination, it could secure a steady niche as part of multi‑drug regimens — especially if it pairs safely with widely used targeted agents. That translates to a meaningful but not automatic blockbuster commercial upside unless Menarini can show clear advantages in efficacy or tolerability versus rivals.
For public companies that make competing SERDs, CDK4/6 inhibitors, PI3K inhibitors, or ADCs, positive signals for ORSERDU change the market calculus subtly: they validate the oral‑SERD approach and may push partners to test new pairings or accelerate their own programs. For Menarini, which is not a household name in global oncology markets, positive Phase 2 data improves its options — it can go it alone, seek partnerships for late‑stage trials, or use the data as leverage in licensing or M&A talks. Investors should watch whether the presentation nudges expectations for future trial designs or sets a more aggressive commercialization plan that would require outside capital or partners.
Key risks, unanswered questions and the next catalysts
The biggest caveats are familiar: Phase 2 data are small and exploratory, follow‑up is limited, and time‑to‑event measures are immature. Without the exact numeric readouts and full safety tables, it’s hard to judge magnitude and durability of benefit or to compare directly to rivals. Regulatory risk is real — broad adoption needs larger, randomized trials showing meaningful patient‑level benefit. Commercial risk includes competition from other oral SERDs or non‑endocrine agents that may erode the pool of patients where ORSERDU could be preferred.
Immediate catalysts to watch are full numeric slides or the company press release with exact ORR, CBR, median DOR/PFS by cohort and by biomarker, updates on which combination(s) Menarini plans to advance, and any announced partnerships or registrational study starts. Those details will determine whether the SABCS readout is a modest scientific update or the opening move of a broader development push.
If you’d like, I can update this story with the precise figures and confidence intervals from Menarini’s SABCS materials — or dig into competitor trial readouts to benchmark the numbers once those full datasets are available.
Photo: Thirdman / Pexels
Sources